The Translational Cancer and Immunity Center (TCIC) aims to achieve a better understanding of the cellular and molecular bases of cancer initiation and progression with a focus on breast cancer, which is the most common type of cancer among females globally.
The TCIC’s highest priority is to shed more light on cancer issues that impact Qatar and the Arab region, areas of the world that are underrepresented in cancer research. A new relevant and contemporary direction for the center is to conduct research in the area of infectious diseases and immunity.
The major focus of the Cancer Research Center is cancer immunology and immunotherapy. More specifically, our research groups are interested in studying the tumor microenvironment and investigating mechanisms utilized by tumor cells to evade immune-mediated destruction. Our specific interests are focused on the role and function of immunosuppressive cells [T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)]. Additionally, we are interested in developing therapeutic approaches against breast cancers by using NK cells, T cells, and genetically modified immune cells. Another major focus of the center is to contribute towards understanding the genetic and epigenetic events leading to tumorigenesis.
To achieve these broad objectives, the Cancer Research Center uses combinations of biochemistry; imaging; proteomic; high throughput genomics; flow cytometry and cell sorting; and bioinformatic technologies as integrative approaches.